Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(16):1186-1188; doi:10.1093/jnci/90.16.1186
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Outwitting Drug Resistance Requires Researchers to Take Many Different Tacks

This is the second of two articles on multidrug resistance in cancer.

Trials are now under way that experts say should give definitive answers about whether multidrug resistance can effectively be reversed in the clinic, making cancer cells more sensitive to chemotherapy.

Other researchers, meanwhile, are developing strategies to make MDR work for rather than against them, using gene transfer techniques to render normal cells more resistant to anticancer drugs.

The different tacks taken by these two lines of research represent the latest efforts to overcome one of the most tenacious problems in clinical oncology, the complexity of which has only recently come to be fully appreciated.


The challenges facing researchers in this field are threefold, wrote Branimir I. Sikic, M.D., director of the General Clinical Research Center at Stanford University Medical Center in California, in an October 1997 review . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?